MA50156A - Variants d'anticorps - Google Patents

Variants d'anticorps

Info

Publication number
MA50156A
MA50156A MA050156A MA50156A MA50156A MA 50156 A MA50156 A MA 50156A MA 050156 A MA050156 A MA 050156A MA 50156 A MA50156 A MA 50156A MA 50156 A MA50156 A MA 50156A
Authority
MA
Morocco
Prior art keywords
antibody variants
variants
antibody
Prior art date
Application number
MA050156A
Other languages
English (en)
Inventor
Esther Maria Furrer
Original Assignee
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59923275&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag
Publication of MA50156A publication Critical patent/MA50156A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MA050156A 2017-09-19 2018-09-11 Variants d'anticorps MA50156A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17191989.7A EP3456738B1 (fr) 2017-09-19 2017-09-19 Variantes d'anticorps

Publications (1)

Publication Number Publication Date
MA50156A true MA50156A (fr) 2020-07-29

Family

ID=59923275

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050156A MA50156A (fr) 2017-09-19 2018-09-11 Variants d'anticorps

Country Status (26)

Country Link
US (2) US11999781B2 (fr)
EP (3) EP4424707A3 (fr)
JP (2) JP7240385B2 (fr)
KR (2) KR102761321B1 (fr)
CN (2) CN111094343B (fr)
AR (1) AR113303A1 (fr)
AU (2) AU2018337495B2 (fr)
BR (1) BR112020005482A2 (fr)
CA (1) CA3075959A1 (fr)
CL (1) CL2020000721A1 (fr)
CO (1) CO2020003260A2 (fr)
CR (2) CR20210205A (fr)
EA (1) EA202090617A1 (fr)
ES (1) ES2991804T3 (fr)
GE (4) GEP20247700B (fr)
IL (2) IL320817A (fr)
JO (1) JOP20200063B1 (fr)
MA (1) MA50156A (fr)
MX (1) MX2020002989A (fr)
PH (1) PH12020500473A1 (fr)
SA (1) SA520411559B1 (fr)
SG (1) SG11202002220TA (fr)
TW (1) TWI873084B (fr)
UA (1) UA129515C2 (fr)
WO (1) WO2019057564A1 (fr)
ZA (1) ZA202001830B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20260151T1 (hr) 2016-08-02 2026-03-27 Visterra, Inc. Modificirani polipeptidi i njihova uporaba
WO2020114616A1 (fr) 2018-12-07 2020-06-11 Tillotts Pharma Ag Traitement topique d'une diarrhée, d'une colite ou d'une entérocolite induite par un inhibiteur de point de contrôle immunitaire au moyen d'anticorps et de fragments de ceux-ci
WO2026055315A1 (fr) 2024-09-05 2026-03-12 Stirx, Inc. Anticorps monoclonaux humanisés, procédés de fabrication et de traitement de neisseria gonorrhea

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296820B2 (en) * 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
DE602005026571D1 (de) * 2004-12-29 2011-04-07 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
CN101120021A (zh) 2004-12-31 2008-02-06 基因技术公司 结合br3的多肽及其用途
HRP20150279T1 (hr) * 2007-12-26 2015-05-08 Xencor, Inc. Fc inaäśice s promijenjenim vezanjem na fcrn
KR102050040B1 (ko) * 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
JP6832707B2 (ja) * 2014-03-26 2021-02-24 セル メディカ スイッツァランド アーゲー ＴＮＦαに対する結合メンバー
CA2945882A1 (fr) * 2014-04-16 2015-10-22 Ucb Biopharma Sprl Proteines fc multimeres
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
CA3011887C (fr) * 2016-03-14 2024-10-29 Universitetet I Oslo Immunoglobulines genetiquement transformees ayant une liaison a fcrn alteree
DK3219726T3 (da) * 2016-03-17 2020-12-07 Tillotts Pharma Ag Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf

Also Published As

Publication number Publication date
JP7402304B2 (ja) 2023-12-20
JP2023036885A (ja) 2023-03-14
SA520411559B1 (ar) 2024-03-19
KR102761321B1 (ko) 2025-02-04
TW201915021A (zh) 2019-04-16
EA202090617A1 (ru) 2020-07-27
US20200216527A1 (en) 2020-07-09
KR20250022222A (ko) 2025-02-14
SG11202002220TA (en) 2020-04-29
JOP20200063B1 (ar) 2024-12-22
UA129515C2 (uk) 2025-05-21
EP3684807A1 (fr) 2020-07-29
GEP20247700B (en) 2024-11-25
CR20210205A (es) 2021-07-27
EP4424707A3 (fr) 2024-11-13
EP3456738B1 (fr) 2024-07-17
IL273351B2 (en) 2025-10-01
US20240343793A1 (en) 2024-10-17
GEP20237484B (en) 2023-03-27
KR20200053514A (ko) 2020-05-18
AU2018337495B2 (en) 2024-10-17
CO2020003260A2 (es) 2020-04-13
EP3456738C0 (fr) 2024-07-17
CN111094343B (zh) 2024-09-20
CN119409817A (zh) 2025-02-11
CR20200132A (es) 2020-07-24
TWI873084B (zh) 2025-02-21
AR113303A1 (es) 2020-04-08
CN111094343A (zh) 2020-05-01
GEAP202215316A (en) 2022-10-25
EP4424707A2 (fr) 2024-09-04
JP2020534307A (ja) 2020-11-26
AU2024287208A1 (en) 2025-02-13
ZA202001830B (en) 2024-10-30
CA3075959A1 (fr) 2019-03-28
AU2018337495A1 (en) 2020-04-09
ES2991804T3 (es) 2024-12-04
PH12020500473A1 (en) 2021-01-25
GEAP202415617A (en) 2024-06-25
MX2020002989A (es) 2020-07-22
JP7240385B2 (ja) 2023-03-15
IL320817A (en) 2025-07-01
IL273351B1 (en) 2025-06-01
BR112020005482A2 (pt) 2020-09-29
JOP20200063A1 (ar) 2020-03-17
US11999781B2 (en) 2024-06-04
EP3456738A1 (fr) 2019-03-20
CL2020000721A1 (es) 2020-08-07
IL273351A (en) 2020-05-31
WO2019057564A1 (fr) 2019-03-28

Similar Documents

Publication Publication Date Title
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
EP3589313A4 (fr) Anticorps anti-tigit
MA49043A (fr) Formulation stable d'anticorps
MA47268A (fr) Anticorps anti-gpc3
EP3784699A4 (fr) Anticorps anti-tl1a optimisés
EP3359573A4 (fr) Marquage d'anticorps
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3484518A4 (fr) Conjugués d'adjuvant d'anticorps
MA44236A (fr) Anticorps anti-tgfbêta 2
EP3498840A4 (fr) Anticorps anti-lag-3
MA49749A (fr) Anticorps anti-cd137
EP3423089A4 (fr) Anticorps anti-tigit
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3692072A4 (fr) Anticorps anti-hla-dq2.5
MA52152A (fr) Anticorps
MA51134A (fr) Anticorps anti-alpha-synucléine
EP3526247A4 (fr) Anticorps anti-il1-rap
MA54052A (fr) Formulation d'anticorps
EP3484919A4 (fr) Anticorps anti-bêta-amyloïde
EP3399992A4 (fr) Anticorps autoréticulants